[Aspirin-exacerbated respiratory disease treated with omalizumab: 3 cases report and literature review].
Zhonghua Jie He He Hu Xi Za Zhi
; 45(12): 1214-1220, 2022 Dec 12.
Article
en Zh
| MEDLINE
| ID: mdl-36480853
ABSTRACT
Objective:
To summarize the clinical data of aspirin-exacerbated respiratory disease (AERD) treated with omalizumab in Peking University First Hospital and reviewed the relative literatures.Methods:
We analyzed retrospectively the clinical data of three cases of AERD treated with omalizumab in Peking University First Hospital from March 1, 2018 to December 31, 2021. The clinical researches on the treatment of AERD with omalizumab up to January 31, 2022 were retrieved in PubMed, China National Knowledge Infrastructure (CNKI) and Wanfang Data.Results:
Our three patients of AERD treated with omalizumab for 32 to 68 weeks obtained relief of symptoms of upper and lower respiratory tract, improvement in lung function, and reduction in percentage of blood eosinophils. There were 14 clinical studies on treatment of AERD with omalizumab, including 3 randomized, double-blind and placebo-controlled studies and 11 self-controlled case series studies. The majority of studies showed that omalizumab contributed to improve the symptoms of AERD, decrease the frequency of asthma attacks and reduce systemic glucocorticoid use.Conclusion:
Omalizumab can improve the disease control of AERD, but further studies are needed.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Aspirina
/
Omalizumab
Tipo de estudio:
Observational_studies
Límite:
Humans
País/Región como asunto:
Asia
Idioma:
Zh
Revista:
Zhonghua Jie He He Hu Xi Za Zhi
Año:
2022
Tipo del documento:
Article
País de afiliación:
China